JP2022500496A5 - - Google Patents
Info
- Publication number
- JP2022500496A5 JP2022500496A5 JP2021537506A JP2021537506A JP2022500496A5 JP 2022500496 A5 JP2022500496 A5 JP 2022500496A5 JP 2021537506 A JP2021537506 A JP 2021537506A JP 2021537506 A JP2021537506 A JP 2021537506A JP 2022500496 A5 JP2022500496 A5 JP 2022500496A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- amino
- piperazine
- triazolo
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024146108A JP2024167310A (ja) | 2018-09-11 | 2024-08-28 | Ａ２ａ阻害剤としてのチオカルバメート誘導体、その医薬組成物、及び抗がん剤との組み合わせ |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729808P | 2018-09-11 | 2018-09-11 | |
| BE2018/0103 | 2018-09-11 | ||
| BE20180103A BE1026758B1 (fr) | 2018-09-11 | 2018-09-11 | Composition pharmaceutique comprenant des dérivés de thiocarbamate inhibiteurs d’a2a |
| US62/729,808 | 2018-09-11 | ||
| US201862737723P | 2018-09-27 | 2018-09-27 | |
| BE20180114A BE1026615B1 (fr) | 2018-09-27 | 2018-09-27 | Combinaison d’un inhibiteur du récepteur a2a et d'un agent anticancéreux |
| BE2018/0114 | 2018-09-27 | ||
| US62/737,723 | 2018-09-27 | ||
| PCT/EP2019/074208 WO2020053263A1 (en) | 2018-09-11 | 2019-09-11 | Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024146108A Division JP2024167310A (ja) | 2018-09-11 | 2024-08-28 | Ａ２ａ阻害剤としてのチオカルバメート誘導体、その医薬組成物、及び抗がん剤との組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022500496A JP2022500496A (ja) | 2022-01-04 |
| JP2022500496A5 true JP2022500496A5 (https=) | 2022-09-21 |
Family
ID=75273324
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537506A Pending JP2022500496A (ja) | 2018-09-11 | 2019-09-11 | Ａ２ａ阻害剤としてのチオカルバメート誘導体、その医薬組成物、及び抗がん剤との組み合わせ |
| JP2024146108A Pending JP2024167310A (ja) | 2018-09-11 | 2024-08-28 | Ａ２ａ阻害剤としてのチオカルバメート誘導体、その医薬組成物、及び抗がん剤との組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024146108A Pending JP2024167310A (ja) | 2018-09-11 | 2024-08-28 | Ａ２ａ阻害剤としてのチオカルバメート誘導体、その医薬組成物、及び抗がん剤との組み合わせ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230121530A1 (https=) |
| EP (2) | EP4410375A3 (https=) |
| JP (2) | JP2022500496A (https=) |
| KR (2) | KR102776112B1 (https=) |
| CN (2) | CN119751480A (https=) |
| AU (1) | AU2019337974A1 (https=) |
| CA (1) | CA3113301A1 (https=) |
| MX (2) | MX2021002865A (https=) |
| WO (1) | WO2020053263A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| AU2018246355B2 (en) | 2017-03-30 | 2021-12-09 | iTeos Belgium SA | 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers |
| EP3621994A4 (en) | 2017-05-12 | 2020-12-30 | Harpoon Therapeutics, Inc. | MESOTHELIN BINDING PROTEINS |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| US11376255B2 (en) | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| AU2020275002A1 (en) | 2019-05-14 | 2021-12-23 | Harpoon Therapeutics, Inc. | EpCAM binding proteins and methods of use |
| WO2021209633A1 (en) * | 2020-04-16 | 2021-10-21 | iTeos Belgium SA | Methods and formulations for administration of thiocarbamate derivatives a2a inhibitors |
| AU2021285044A1 (en) * | 2020-06-03 | 2022-12-08 | Institute For Research In Biomedicine | Combination of an ATP-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof |
| WO2022032091A1 (en) * | 2020-08-07 | 2022-02-10 | Teon Therapeutics, Inc. | Combination therapy with adenosine receptor antagonists |
| CA3208069A1 (en) * | 2021-03-09 | 2022-09-15 | Mary Ellen Molloy | Combination therapy with immune cell engaging proteins and immunomodulators |
| KR102646627B1 (ko) * | 2021-03-24 | 2024-03-13 | 주식회사 스탠다임 | 아데노신 a2a 수용체 및 아데노신 a2b 수용체의 이중 길항제, 및 이의 용도 |
| JP2024538686A (ja) * | 2021-10-07 | 2024-10-23 | アイテオ ベルギウム エスエー | イヌパデナントの塩酸塩、医薬組成物およびその使用の方法 |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| WO2024214044A1 (en) * | 2023-04-12 | 2024-10-17 | iTeos Belgium SA | Multicomponent complexes, including salts and hydrates and solvates, of inupadenant |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE461932T1 (de) * | 2004-04-21 | 2010-04-15 | Schering Corp | Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors |
| AU2011306358B2 (en) * | 2010-09-24 | 2014-08-14 | Impetis Biosciences Ltd. | Fused tricyclic compounds as adenosine receptor antagonist |
| WO2012135084A1 (en) * | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| MX368257B (es) * | 2011-08-01 | 2019-09-26 | Genentech Inc | Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer. |
| US9301920B2 (en) * | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| DK3016946T3 (da) * | 2013-07-03 | 2023-01-09 | Karyopharm Therapeutics Inc | Substituerede benzofuranyl- og benzoxazolylforbindelser og anvendelser deraf |
| EA201650031A1 (ru) | 2014-05-15 | 2017-06-30 | Итеос Терапьютик | Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1 |
| PE20181046A1 (es) | 2015-09-25 | 2018-07-03 | Genentech Inc | Anticuerpos anti-tigit y metodos de uso |
| EP3589313A4 (en) | 2017-02-28 | 2021-05-19 | Seagen Inc. | ANTI-TIGITE ANTIBODY |
| TWI801372B (zh) * | 2017-03-30 | 2023-05-11 | 比利時商艾特歐斯比利時有限公司 | 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法 |
| AU2018246355B2 (en) * | 2017-03-30 | 2021-12-09 | iTeos Belgium SA | 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers |
| WO2019023504A1 (en) | 2017-07-27 | 2019-01-31 | Iteos Therapeutics Sa | ANTI-TIGIT ANTIBODIES |
| IL272227B2 (en) | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| IL281802B2 (en) * | 2018-09-27 | 2025-10-01 | iTeos Belgium SA | Use of an ENT family transporter inhibitor in cancer treatment and its combination with an adenosine receptor antagonist |
-
2019
- 2019-09-11 AU AU2019337974A patent/AU2019337974A1/en not_active Abandoned
- 2019-09-11 EP EP24179691.1A patent/EP4410375A3/en active Pending
- 2019-09-11 JP JP2021537506A patent/JP2022500496A/ja active Pending
- 2019-09-11 CN CN202411795158.2A patent/CN119751480A/zh active Pending
- 2019-09-11 WO PCT/EP2019/074208 patent/WO2020053263A1/en not_active Ceased
- 2019-09-11 KR KR1020217010619A patent/KR102776112B1/ko active Active
- 2019-09-11 EP EP19772998.1A patent/EP3849558B1/en active Active
- 2019-09-11 CA CA3113301A patent/CA3113301A1/en active Pending
- 2019-09-11 MX MX2021002865A patent/MX2021002865A/es unknown
- 2019-09-11 CN CN201980073376.6A patent/CN113226324B/zh active Active
- 2019-09-11 KR KR1020257006579A patent/KR20250035608A/ko not_active Ceased
-
2021
- 2021-03-10 MX MX2023010979A patent/MX2023010979A/es unknown
-
2022
- 2022-06-01 US US17/829,919 patent/US20230121530A1/en not_active Abandoned
-
2024
- 2024-08-28 JP JP2024146108A patent/JP2024167310A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500496A5 (https=) | ||
| EP4096671B1 (en) | Combination therapy for treating abnormal cell growth | |
| US20230121530A1 (en) | Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents | |
| JP6933770B2 (ja) | Ｈｉｖカプシド阻害剤のコリン塩形態 | |
| JP2024170471A (ja) | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 | |
| AU2014372166B2 (en) | Pharmaceutical combinations | |
| IL269710B2 (en) | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in cancer therapy | |
| US20170224672A1 (en) | Drug Combinations to Treat Multiple Myeloma | |
| IL281802B1 (en) | Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist | |
| JP2021523169A (ja) | ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法 | |
| JP2024544625A (ja) | がんを処置するためのｃｄｋ２阻害剤およびｃｄｋ４阻害剤を含む方法および投薬レジメン | |
| JP2021523189A (ja) | ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組成物およびその使用方法 | |
| EP4048251A1 (en) | Compositions comprising a dhodh inhibitor for the treatment of acute myeloid leukemia | |
| RU2005136131A (ru) | Фармацевтическая композиция, содержащая антагонист р2х7 рецептора и фактор некроза опухоли | |
| JP2021523190A (ja) | 腺様嚢胞癌を治療するためのビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組成物 | |
| JP2020521786A5 (https=) | ||
| RU2021109332A (ru) | Производные тиокарбамата в качестве ингибиторов a2a, их фармацевтические композиции и комбинации с противораковыми средствами | |
| US11376255B2 (en) | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents | |
| WO2023281097A1 (en) | Methods for treating cancer | |
| JPWO2018186366A1 (ja) | 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤 | |
| US20210338672A1 (en) | Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist | |
| JP2026502548A (ja) | 光学活性なアザビシクロ環誘導体を含むがんの治療剤 | |
| TW201642866A (zh) | ４－（４－氟－２－甲氧苯基）－ｎ－｛３－［（ｓ－甲基磺醯亞胺醯基）甲基］苯基｝－１，３，５－三－２－胺於治療淋巴癌之用途 | |
| JP2018509439A (ja) | 多発性骨髄腫を治療するための４−（４−フルオロ−２−メトキシフェニル）−ｎ−｛３−［（ｓ−メチルスルホンイミドイル）メチル］フェニル｝−１，３，５−トリアジン−２−アミンの使用 | |
| HK40116611A (zh) | 用於治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案 |